Literature DB >> 28895294

Pathology of self-expanding transcatheter aortic valves: Findings from the CoreValve US pivotal trials.

Kazuyuki Yahagi1, Sho Torii1, Elena Ladich1, Robert Kutys1, Maria E Romero1, Hiroyoshi Mori1, Frank D Kolodgie1, Jeffrey J Popma2, Renu Virmani1, Aloke V Finn1.   

Abstract

BACKGROUND: Transcatheter aortic valve replacement (TAVR) has recently become an alternative to surgical aortic valve replacement for patients with severe aortic stenosis. However, paravalvular leaks, possible leaflet thrombosis, and device durability following TAVR remain unresolved issues. METHODS AND
RESULTS: We conducted the first systematic microscopic and macroscopic pathologic analysis of self-expanding CoreValve transcatheter aortic valves removed at autopsy or surgically from the U.S. pivotal trial of extreme- and high-risk patients. Implants were evaluated for histopathologic changes in the valve frame and leaflets. Thrombus/neointima on the leaflets was graded depending on the leaflet thickness and the extent of leaflet involvement. Inflammation, calcification, and structural integrity were also assessed. A total of 21 cases (median age 86.0 years [IQR, 79.0-91.0]), with median duration of implant duration of 17.0 days ranged from 0 to 503 days were evaluated. No valve frame fracture was observed and severe paravalvular gaps were uncommon. Inflammation and thrombus in the valve frame was minimal, but neointimal growth increased overtime. Symptomatic valve thrombosis was observed in one case (5%) and subclinical moderate leaflet thrombus was observed in four additional cases (19%). Inflammation of the leaflets was mild, while structural changes were minimal, and one case had infective endocarditis. Pannus or leaflet calcification were not observed.
CONCLUSIONS: This first systematic macroscopic and microscopic pathologic analysis of self-expanding transcatheter aortic valves demonstrates favorable short-term pathologic findings. However, our finding of subclinical leaflet thrombus formation confirms prior observations and warrants further investigation.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  CoreValve; TAVR; pathology; self-expanding trancatheter aortic valve; valve thrombus

Mesh:

Year:  2017        PMID: 28895294     DOI: 10.1002/ccd.27314

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  3 in total

1.  Reoperation After Transcatheter Aortic Valve Replacement: An Analysis of the Society of Thoracic Surgeons Database.

Authors:  Oliver K Jawitz; Brian C Gulack; Maria V Grau-Sepulveda; Roland A Matsouaka; Michael J Mack; David R Holmes; John D Carroll; Vinod H Thourani; J Matthew Brennan
Journal:  JACC Cardiovasc Interv       Date:  2020-06-10       Impact factor: 11.195

2.  Transcatheter aortic valve replacements alter circulating serum factors to mediate myofibroblast deactivation.

Authors:  Brian A Aguado; Katherine B Schuetze; Joseph C Grim; Cierra J Walker; Anne C Cox; Tova L Ceccato; Aik-Choon Tan; Carmen C Sucharov; Leslie A Leinwand; Matthew R G Taylor; Timothy A McKinsey; Kristi S Anseth
Journal:  Sci Transl Med       Date:  2019-09-11       Impact factor: 19.319

3.  Transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis: a systematic review and meta-analysis.

Authors:  Stephanie Louise Swift; Thomas Puehler; Kate Misso; Shona Helen Lang; Carol Forbes; Jos Kleijnen; Marion Danner; Christian Kuhn; Assad Haneya; Hatim Seoudy; Jochen Cremer; Norbert Frey; Georg Lutter; Robert Wolff; Fueloep Scheibler; Kai Wehkamp; Derk Frank
Journal:  BMJ Open       Date:  2021-12-06       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.